News und Analysen
![Dexcom Announces Upcoming Conference Presentation](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
-
Steven Pacelli, Executive Vice President, Strategy and
![Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Xencor to Present Initial Data from the Phase 1 Study of XmAb®13676 in B-Cell Malignancies at the American Society of Hematology Annual Meeting
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases
![American Renal Associates Holdings, Inc. Announces Third Quarter 2019 Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
American Renal Associates Holdings, Inc. Announces Third Quarter 2019 Results
American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and
![Puma Biotechnology Reports Third Quarter 2019 Financial Results](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Puma Biotechnology Reports Third Quarter 2019 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2019. Unless otherwise stated, all comparisons are for
![Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
![Xencor Reports Third Quarter 2019 Financial Results](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Xencor Reports Third Quarter 2019 Financial Results
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases
![Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Vifor Pharma Enters Into Commercial Collaboration in the US with Janssen
Regulatory News:
Vifor Pharma today announced a commercial partnership with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to jointly
![Stoke Therapeutics to Present at Upcoming Investor Conferences in November](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Stoke Therapeutics to Present at Upcoming Investor Conferences in November
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression, today
![Veeva to Release Fiscal 2020 Third Quarter Results on November 26, 2019](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Veeva to Release Fiscal 2020 Third Quarter Results on November 26, 2019
Veeva Systems (NYSE:VEEV) will announce financial results for its third quarter which ended October 31, 2019 after the market close on November 26, 2019. Veeva will host a conference call and
![Almirall Makes Shift to Specialty Medicine with Veeva CRM](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Almirall Makes Shift to Specialty Medicine with Veeva CRM
Veeva Systems (NYSE:VEEV) today announced that Almirall selected multichannel Veeva CRM to deliver seamless customer experience across all channels as it shifts business focus to specialty
![Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that it will report
![Veeva Completes Acquisition of Crossix](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Veeva Completes Acquisition of Crossix
Veeva Systems (NYSE:VEEV) today announced it has completed its acquisition of Crossix Solutions. Trusted by more than 200 pharmaceutical brands, Crossix provides privacy-safe U.S. patient data and
![IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
IMV Inc. Announces Third Quarter 2019 Financial Results and Provides Corporate Update
IMV Inc. (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the third quarter
![QIAGEN stellt auf der AMP-Jahreskonferenz 2019 einen neuen NGS-Workflow für die simultane DNA- und RNA-Analyse zum Einsatz im Krebs-Profiling vor](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
QIAGEN stellt auf der AMP-Jahreskonferenz 2019 einen neuen NGS-Workflow für die simultane DNA- und RNA-Analyse zum Einsatz im Krebs-Profiling vor
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute die Erweiterung seines QIAseg-NGS-Portfolios bekannt. Das Unternehmen bietet künftig einen eintägigen Workflow für die simultane
![Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Waters Advanced Polymer Chromatography System Now First Fully Solvent-Compatible UPLC System for Greater Flexibility and Speed
Waters Corporation (NYSE:WAT) announced today that its ACQUITY™ Advanced Polymer Chromatography™ (APC™) System is the first fully solvent-compatible UltraPerformance Liquid Chromatography
![The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019
The Medicines Company (NASDAQ:MDCO) today announced that detailed results from the ORION-9 and ORION-10 pivotal Phase 3 clinical studies of inclisiran will be presented during late-breaking science
![Charles River Laboratories Announces Third-Quarter 2019 Results](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Charles River Laboratories Announces Third-Quarter 2019 Results
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3
![Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019
Regulatory News:
Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic
![NanoString Announces Availability of the GeoMx Cancer Transcriptome Atlas Through the Technology Access Program for Digital Spatial Profiling](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
NanoString Announces Availability of the GeoMx Cancer Transcriptome Atlas Through the Technology Access Program for Digital Spatial Profiling
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced the availability of its new
![Premier Inc. Reports Fiscal 2020 First-Quarter Results](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Premier Inc. Reports Fiscal 2020 First-Quarter Results
Premier Inc. (NASDAQ: PINC) today reported financial results for the fiscal 2020 first quarter ended Sept. 30, 2019.
All results presented in the following release reflect those of continuing
![Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Bionomics Announces Fast Track Designation Granted by U.S. FDA to BNC210 Development Program for the Treatment of PTSD
Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a global, clinical stage biopharmaceutical company discovering and developing a pipeline of novel drug candidates targeting ion channels, announced today
![Dexcom Reports Third Quarter 2019 Financial Results](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Dexcom Reports Third Quarter 2019 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2019.
Third Quarter 2019 Highlights:
-
Revenue grew 49% versus the same quarter of
![Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Ipsen Appoints Howard Mayer, M.D. as Executive Vice President and Head of Research and Development
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191104006077/en/
Dr. Howard Mayer, Executive Vice-President and Head
![Clovis Oncology Announces Third Quarter 2019 Operating Results](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Clovis Oncology Announces Third Quarter 2019 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2019, and provided an update on Clovis’ clinical development programs and regulatory and
![Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will